Yicheng Guo

A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants

The paper develops a monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants and identifies differences in antibody-evasion profiles between JN.1 and BA.3.2 lineages.

Antibody evasion and receptor binding of SARS-CoV-2 RW.1.1

This study evaluates antibody evasion and ACE2 receptor engagement of SARS-CoV-2 variant RW.1.1, finding reduced receptor binding but no increased serum resistance compared to other variants.

SARS-CoV-2 BA.3.2.2 is more evasive of neutralization by sera from young children

This study finds that young children have lower neutralizing antibody titers against BA.3.2.2 compared to adults, despite similar titers against dominant variants, suggesting age-related differences in susceptibility.

A Panel of Human Monoclonal Antibodies for Tracking the Antigenic Evolution of Influenza H5N1 Clade 2.3.4.4b

This study generates 19 human monoclonal antibodies to track antigenic evolution of H5N1 clade 2.3.4.4b, identifying epitope-specific neutralization patterns and antigenic differences between viral genotypes.

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individuals

This study evaluates VYD2311, a new monoclonal antibody, showing it neutralizes multiple SARS-CoV-2 variants more effectively than pemivibart, making it a potential candidate for immunocompromised individuals.

HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D gene

This study isolates and characterizes V2 apex-directed neutralizing antibodies from SHIV-infected macaques, revealing structural and genetic features that enable broad neutralization.

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2

This study optimizes a human monoclonal antibody to enhance its neutralization of SARS-CoV-2 variants, including subvariants XEC and LP.8.1, through structural analysis and engineering.

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages

This study evaluates pemivibart's neutralizing activity against recent SARS-CoV-2 JN.1 sublineages and finds it has substantially reduced potency against KP.3.1.1.

Meta-analysis of exhausted CD8+ T cells from Homo sapiens and Mus musculus provides robust targets for immunotherapy

This study performs a meta-analysis of exhausted CD8+ T cells in humans and mice to identify robust therapeutic targets for immunotherapy.

Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH

This study identifies two new PAH risk genes, FBLN2 and PDGFD, through rare variant analysis of 4,241 PAH cases, with de novo variants contributing to ~15% of pediatric IPAH.

cAb-Rep: A Database of Curated Antibody Repertoires for Exploring antibody diversity and Predicting Antibody Prevalence

cAb-Rep is a curated database of human B cell immunoglobulin sequence repertoires, providing annotated datasets for studying antibody diversity and prevalence.

Efficient repositioning of approved drugs as anti-HIV agents using Anti-HIV-Predictor

The paper develops a web server to predict anti-HIV activity of compounds and identifies 7 approved drugs repurposed as anti-HIV agents.